Last reviewed · How we verify
Tenofovir Disoproxil, Lamuvidine and Dolutegravir
Tenofovir Disoproxil, Lamuvidine and Dolutegravir is a NRTI/INST Small molecule drug developed by Africa Health Research Institute. It is currently in Phase 3 development for Treatment of HIV-1 infection in adults and pediatric patients, Prevention of mother-to-child transmission of HIV.
Tenofovir Disoproxil is a nucleotide reverse transcriptase inhibitor, Lamivudine is a nucleoside reverse transcriptase inhibitor, and Dolutegravir is an integrase strand transfer inhibitor.
Tenofovir Disoproxil is a nucleotide reverse transcriptase inhibitor, Lamivudine is a nucleoside reverse transcriptase inhibitor, and Dolutegravir is an integrase strand transfer inhibitor. Used for Treatment of HIV-1 infection in adults and pediatric patients, Prevention of mother-to-child transmission of HIV.
At a glance
| Generic name | Tenofovir Disoproxil, Lamuvidine and Dolutegravir |
|---|---|
| Sponsor | Africa Health Research Institute |
| Drug class | NRTI/INST |
| Target | HIV-1 reverse transcriptase, HIV-1 integrase |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
Tenofovir Disoproxil, Lamivudine, and Dolutegravir work together to inhibit viral replication by targeting different stages of the HIV life cycle. Tenofovir Disoproxil inhibits the reverse transcription of viral DNA, Lamivudine inhibits the reverse transcription of viral DNA, and Dolutegravir inhibits the integration of viral DNA into the host genome.
Approved indications
- Treatment of HIV-1 infection in adults and pediatric patients
- Prevention of mother-to-child transmission of HIV
Common side effects
- Nausea
- Diarrhea
- Headache
- Fatigue
- Dizziness
Key clinical trials
- Long-Acting HIV Pre-Exposure Prophylaxis Integrated With Sexual and Reproductive Health - cRCT (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tenofovir Disoproxil, Lamuvidine and Dolutegravir CI brief — competitive landscape report
- Tenofovir Disoproxil, Lamuvidine and Dolutegravir updates RSS · CI watch RSS
- Africa Health Research Institute portfolio CI
Frequently asked questions about Tenofovir Disoproxil, Lamuvidine and Dolutegravir
What is Tenofovir Disoproxil, Lamuvidine and Dolutegravir?
How does Tenofovir Disoproxil, Lamuvidine and Dolutegravir work?
What is Tenofovir Disoproxil, Lamuvidine and Dolutegravir used for?
Who makes Tenofovir Disoproxil, Lamuvidine and Dolutegravir?
What drug class is Tenofovir Disoproxil, Lamuvidine and Dolutegravir in?
What development phase is Tenofovir Disoproxil, Lamuvidine and Dolutegravir in?
What are the side effects of Tenofovir Disoproxil, Lamuvidine and Dolutegravir?
What does Tenofovir Disoproxil, Lamuvidine and Dolutegravir target?
Related
- Drug class: All NRTI/INST drugs
- Target: All drugs targeting HIV-1 reverse transcriptase, HIV-1 integrase
- Manufacturer: Africa Health Research Institute — full pipeline
- Therapeutic area: All drugs in Infectious Diseases
- Indication: Drugs for Treatment of HIV-1 infection in adults and pediatric patients
- Indication: Drugs for Prevention of mother-to-child transmission of HIV
- Compare: Tenofovir Disoproxil, Lamuvidine and Dolutegravir vs similar drugs
- Pricing: Tenofovir Disoproxil, Lamuvidine and Dolutegravir cost, discount & access